NEJM Journal Watch

An editorially independent, go-to-source for clinicians since 1987, NEJM Journal Watch is among the principal products of NEJM Group. The mission of NEJM Group is to advance medical knowledge from research to patient care, making the connections between developments in clinical science and clinical practice to improve healthcare quality and patient outcomes. NEJM Journal Watch helps clinicians save time and stay informed by providing them with brief, clearly written, clinically focused perspectives on the medical developments that affect practice. Its editors -- practicing physicians and thought leaders in their fields -- survey the medical literature, select the most important research and guidelines, distill them into focused summaries, and frame them in a clinical context. In addition, NEJM Journal Watch covers the most important medical news, drug information, and public health alerts.

For more information, visit www.jwatch.org.

Latest by NEJM Journal Watch

For Our Stable HIV Patients, Why Are We Still Sending All These Lab Tests So Often?

Do the guidelines for laboratory monitoring still make sense when our HIV treatments have become so safe and effective? Paul E. Sax, M.D., offers a revised -- and deliberately provocative -- recommendation.

By Paul E. Sax, M.D. for NEJM Journal Watch

As a Strategy for HIV Prevention, Disabling the CCR5 Gene in Embryos Implanted in HIV-Negative Mothers Makes Zero Sense

Paul Sax, M.D., puts it bluntly: "[I]t makes zero sense to do this since the babies aren't at risk of getting HIV to begin with."

By Paul E. Sax, M.D. for NEJM Journal Watch

HIV and HCV Treatment, Shorter Antibiotic Courses, Malaria-Sniffing Dogs, and Other ID and HIV Reasons to Be Grateful, 2018 Edition

Just in time for Thanksgiving, Paul Sax, M.D., provides a rundown of developments that infectious disease and HIV specialists can be grateful for over the past year.

By Paul E. Sax, M.D. for NEJM Journal Watch

Doravirine Sets a New Standard for NNRTIs -- but What Role in HIV Treatment Today?

"Since this appears to be a 'best in class' drug, doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one," writes Paul Sax, M.D.

By Paul E. Sax, M.D. for NEJM Journal Watch

Why Caring for People With HIV Is Still Great

"I truly believe that HIV care remains an extraordinarily gratifying aspect of ID clinical practice," Paul Sax, M.D., writes. "Which is why it’s critical that ID doctors continue to do it."

By Paul E. Sax, M.D. for NEJM Journal Watch

Really Rapid Review: International AIDS Conference 2018, Amsterdam

Paul Sax, M.D., provides highlights of the important and interesting studies that caught his eye at AIDS 2018.

By Paul E. Sax, M.D. for NEJM Journal Watch

FDA Approves First PI-Based Single-Tablet Treatment for HIV -- How Will It Be Used?

Paul Sax, M.D., says that while most patients prefer the simplicity of having one pill, one prescription, and one co-pay, the new Symtuza (D/C/F/TAF) tablet faces several challenges that may limit widespread adoption.

By Paul E. Sax, M.D. for NEJM Journal Watch

Surgeon Who Was Denied Disability Insurance for Taking PrEP Tells His Story

Earlier this year, urology resident Philip Cheng, M.D., appeared on the front page of The New York Times explaining his situation. Now, in a podcast, he tells Paul Sax, M.D., more about himself and the events surrounding his decision to go public....

By Paul E. Sax, M.D. for NEJM Journal Watch

Why the Dolutegravir Pregnancy Warning Is Important -- and What We Should Do Now

There are several reasons why this warning is important -- and why the best treatment for women with HIV who want children remains an open question.

By Paul E. Sax, M.D. for NEJM Journal Watch

Why Experienced HIV/ID Doctors Leave Clinical Practice

After the departure from clinical practice of three colleagues, Paul Sax, M.D., reflects on the state of U.S. health care and its frustrating "medicine-as-a-business" model.

By Paul E. Sax, M.D. for NEJM Journal Watch